VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISAL 2019 | Bispecific antibodies for R/R AML: ongoing clinical trials

Bispecific antibodies are moving from strength to strength, with a multitude in clinical trials. Here, John DiPersio, MD, PhD, of Washington University School of Medicine, Washington, WA, discusses the bispecific antibodies under investigation for relapsed/refractory acute myeloid leukemia (AML), typically targeting CD123, CD33 or CLL1. Prof. DiPersio was speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter